References

American Academy of Pediatrics. Summaries of infectious diseases: molluscum contagiosum. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021–2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021:535-537.

Badri T, Gandhi GR. Molluscum contagiosum. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing; 2023. Updated March 27, 2023. Accessed December 12, 2023. https://www.ncbi.nlm.nih.gov/books/NBK441898

Berger EM, Orlow SJ, Patel RR, Schaffer JV. Experience with molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: the bump that rashes. Arch Dermatol. 2012;148(11):1257-1264.

Bugert JJ. Genus Molluscipoxvirus. In: Mercer AA, Schmidt A, Weber O, eds. Poxviruses. Birkhäuser Verlag; 2007:89-112.

Data on file. Verrica Pharmaceuticals Inc.

Eichenfield LF, McFalda W, Brabec B, et al. Pooled results of two, phase 3 studies with VP-102 for the topical treatment of molluscum contagiosum: ≥75% and ≥90% clearance rates for treated lesions in CAMP-1 and CAMP-2. Poster presented at: Fall Clinical Dermatology Symposium; October 17-20, 2019; Las Vegas, NV.

Eichenfield LF, McFalda W, Brabec B, et al. Safety and efficacy of VP-102, a proprietary, drug-device combination product containing cantharidin, 0.7% (w/v), in children and adults with molluscum contagiosum: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(12):1315-1323.

Eichenfield LF, Siegfried E, Kwong P, et al. Pooled results of two randomized phase III trials evaluating VP‐102, a drug‐device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum. Am J Clin Dermatol. 2021;22(2):257-265.

Eichenfield LF, Willson C, McBride M, Davidson M, Burnett P. CAMP-1 and CAMP-2: phase 3, randomized, double-blind, vehicle-controlled, pivotal studies investigating VP-102, a novel drug-device combination containing a topical formulation of cantharidin for the treatment of molluscum contagiosum. Poster presented at: Integrative Dermatology Symposium; October 3-5, 2019; San Diego, CA.

Kwong P, Hebert AA, Utley C, Olivadoti M. The hidden impact of molluscum contagiosum: a survey of caregivers’ experiences with diagnosis, treatment, and impact on quality of life. SKIN The Journal of Cutaneous Medicine. 2021;5(4):363-371.

Lacarrubba F, Micali G, Trecarichi AC, Quattrocchi E, Monfrecola G, Verzi AE. New developing treatments for molluscum contagiosum. Dermatol Ther (Heidelb). 2022;12(12):2669-2678.

Leung AK, Barankin B. Molluscum contagiosum in atopic dermatitis. HMP Global Learning Network. Published December 2015. Accessed November 20, 2023. https://www.hmpgloballearningnetwork.com/site/thederm/site/cathlab/event/molluscum-contagiosum-atopic-dermatitis

Meza-Romero R, Navarrete-Dechent C, Downey C. Molluscum contagiosum: an update and review of new perspectives in etiology, diagnosis, and treatment. Clin Cosmet Investig Dermatol. 2019;12:373-381.

Moed L, Shwayder TA, Chang MW. Cantharidin revisited: a blistering defense of an ancient medicine. Arch Dermatol. 2001;137(10):1357-1360.

Molluscum contagiosum: overview. American Academy of Dermatology Association. Accessed November 20, 2023. https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview

Nemeth V, Evans J. Eczema. In: StatPearls. NCBI Bookshelf version. StatPearls Publishing; 2022. Updated August 8, 2022. Accessed November 20, 2023. https://www.ncbi.nlm.nih.gov/books/NBK538209

Olsen JR, Gallacher J, Finlay AY, Piguet V, Francis NA. Time to resolution and effect on quality of life of molluscum contagiosum in children in the UK: a prospective community cohort study. Lancet Infect Dis. 2015;15(2):190-195.

Safely treating molluscum, a common skin condition. US Food and Drug Administration. Updated August 23, 2023. Accessed November 29, 2023.  https://www.fda.gov/consumers/consumer-updates/safely-treating-molluscum-common-skin-condition

Schaffer JV, Berger EM. Molluscum contagiosum. JAMA Dermatol. 2016;152(9):1072.

Silverberg NB. Pediatric molluscum: an update. Cutis. 2019;104(5):301-305;E1;E2.

Torbeck R, Pan M, de Moll E, Levitt J. Cantharidin: a comprehensive review of the clinical literature. Dermatol Online J. 2014;20(6):13030/qt45r512w0.

van der Wouden JC, van der Sande R, Kruithof EJ, Sollie A, van Suijlekom-Smit LWA, Koning S. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev. 2017;5(5):CD004767.

Verrica Pharmaceuticals announces FDA acceptance of filing of resubmitted NDA for VP-102 for the treatment of molluscum contagiosum. News release. February 27, 2023. Accessed November 20, 2023. https://verrica.com/press_release/fda-accepts-resubmitted-filing-for-vp-102-for-the-treatment-of-molluscum-contagiosum

YCANTH™. Package insert. Verrica Pharmaceuticals Inc.; 2023.

INDICATION:

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION:

What warnings should I know about YCANTH?

Do not get YCANTH in the mouth, nose, or eyes, and do not let YCANTH touch healthy skin. Life threatening or fatal toxicities can occur if YCANTH is taken by mouth. Avoid contact with areas of the body that have been treated, including contact by mouth. Damage to the eyes can occur if YCANTH comes in contact with the eyes. If YCANTH gets in the eyes, rinse eyes with water for at least 15 minutes.
Local skin side effects at the application site may occur, including blistering, itching, pain, discoloration, and redness. Do not get YCANTH in the mouth, nose, or eyes, and do not let YCANTH touch healthy skin. If YCANTH contacts any unintended surface or healthy skin, immediately remove. If severe blistering, severe pain, or other severe skin side effects occur, wash off YCANTH immediately and contact your healthcare provider.
YCANTH is flammable, even after drying. Do not expose YCANTH-treated areas to fire, flame, or smoke until YCANTH is washed off.
Do not use YCANTH if you are allergic to any of the ingredients in YCANTH. The active ingredient in YCANTH is cantharidin. The inactive ingredients are acetone, camphor, castor oil, denatonium benzoate, ethanol, gentian violet, hydroxypropyl cellulose, and nitrocellulose.

What are the possible side effects of YCANTH?

The most common side effects are local skin side effects at the application site, including blistering, pain, itching, scabbing, redness, discoloration, dryness, swelling, and loss of the outer layer of skin at the application site. These local skin side effects are expected and are related to the anticipated blistering caused by YCANTH.

Do other medications interact with YCANTH?

It is not currently known if any medications interact with YCANTH.

Can I use YCANTH if I’m pregnant?

The potential risk of YCANTH for major birth defects, miscarriage, or maternal or fetal side effects is unknown. Given that YCANTH is applied to the outside of the mother’s skin, use is not expected to result in exposure of YCANTH to unborn babies.

Can I use YCANTH if I’m breastfeeding?

Do not use YCANTH on areas of the mother’s body where YCANTH may come in contact with the breastfeeding child’s mouth or eyes.

What should I do if YCANTH is swallowed?

Taking cantharidin by mouth has resulted in kidney failure, blistering and severe damage to the stomach and intestines, excessive bleeding or clotting, seizures, and weakness or paralysis. Seek medical attention immediately if YCANTH is accidentally ingested.

These are not all the possible side effects of YCANTH. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. You may also report side effects to Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422). Local skin side effects are expected and should be reported if they are severe.

Please see full Prescribing Information.